iRegene Therapeutics Revenue and Competitors
Employee Data
- iRegene Therapeutics has 5 Employees.
- iRegene Therapeutics grew their employee count by -17% last year.
iRegene Therapeutics's People
| Name | Title | Email/Phone |
|---|
iRegene Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | N/A | 7 | 75% | N/A | N/A |
#2 | N/A | 8 | 0% | N/A | N/A |
#3 | N/A | 5 | -17% | N/A | N/A |
#4 | N/A | 7 | 17% | N/A | N/A |
#5 | N/A | 16 | -6% | N/A | N/A |
#6 | N/A | 4 | 33% | N/A | N/A |
#7 | N/A | 22 | -12% | N/A | N/A |
#8 | N/A | 5 | 25% | N/A | N/A |
#9 | N/A | 46 | 2% | N/A | N/A |
#10 | N/A | 15 | 25% | N/A | N/A |
What Is iRegene Therapeutics?
We research and develop proprietary chemically-derived allogeneic cell therapy for degenerative diseases like Parkinson’s Disease, Retinal Degenerative Diseases, Ischemic Stroke, etc. \n\nOur leading pipeline NouvNeu001 (Parkinson’s Disease) is scheduled to initiate Phase I clinical trial in 2023 H2.\n\nWe are a passionate team committed to developing first-in-class therapies for patients suffering from major incurable diseases. Making fast-acting and disease-reversing therapies accessible to patients in the greatest extent possible is our priority.
keywords:N/A
N/A
Total Funding
5
Number of Employees
N/A
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Wuhan
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.6M | 13 | N/A | N/A |
#2 | $0.8M | 18 | N/A | N/A |
#3 | $3.9M | 60 | N/A | N/A |
#4 | $23.1M | 84 | 6% | N/A |
#5 | $30.7M | 87 | 6% | N/A |